On the stock market since 2019, it operates in the world of money and finance. It has 13 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
No real growth (2% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
The stock trades 31% below its peak. The market has trimmed its expectations for the company.
Sales run at $4.1M a year. A small number, but proof the product has real buyers.
A loss of $476K against $4.1M in annual sales. And on top of that, sales fell from the year before.
On our five-subject report card, ERKH sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ERKH is a high-risk stock — not yet profitable, and its future rides on its product catching on.